Sunitinib combined with pemetrexed and carboplatin in patients with NSCLC and other advanced solid malignancies: maximum tolerated dose and safety results

被引：0
|
作者：
Chow, Laura Q. M. [1 ]
Blais, Normand [2 ]
Jonker, Derek J. [1 ]
Soulieres, Denis [2 ]
Laurie, Scott A. [1 ]
Diab, Sami G. [3 ]
Ruiz-Garcia, Ana [4 ]
Thall, Aron [4 ]
Chao, Richard [4 ]
Eckhardt, S. Gail [5 ]
Camidge, D. Ross [5 ]
机构：
[1] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] CHUM, Hop Notre Dame de Bon Secours, Montreal, PQ, Canada
[3] Rocky Mt Canc Ctr, Aurora, CO USA
[4] Pfizer Oncol, La Jolla, CA USA
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S672 / S672
页数：1
相关论文
共 50 条
  • [41] BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination
    Scheffler, M.
    Gardizi, M.
    Bos, M.
    Nogova, L.
    Papachristou, I.
    Persigehl, T.
    Dietlein, F.
    Zander, T.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 131 - 131
  • [42] Determination of the maximum tolerated dose of cyclophosphamide in conjunction with high-dose etoposide and carboplatin followed by autologous CD34+hematopoietic rescue in pediatric patients with recurrent/refractory solid tumors.
    Hudspeth, Michelle P.
    Duffy, Barbara
    Noga, Stephen
    Goodman, Steven
    Civin, Curt I.
    Chen, Allen R.
    BLOOD, 2006, 108 (11) : 461B - 461B
  • [43] Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies.
    Weiner, LM
    Belldegrun, A
    Rowinsky, E
    Crawford, J
    Lockbaum, P
    Huang, S
    Arends, R
    Schwab, G
    Figlin, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 206S - 206S
  • [44] Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
    Li, X.
    Zheng, X.
    An, J.
    Hua, Y.
    Ding, X.
    Shi, H.
    Xu, W.
    Li, Y.
    Zhou, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [45] An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
    Schilder, Russell J.
    Rasco, Drew
    Sharma, Manish R.
    NEOPLASIA, 2025, 61
  • [46] Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
    Leong, Stephen
    Cohen, Roger B.
    Gustafson, Daniel L.
    Langer, Corey J.
    Camidge, D. Ross
    Padavic, Kristin
    Gore, Lia
    Smith, Margaret
    Chow, Laura Q.
    von Mehren, Margaret
    O'Bryant, Cindy
    Hariharan, Sujatha
    Diab, Sami
    Fox, Norma Lynn
    Miceli, Renee
    Eckhardt, S. Gail
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4413 - 4421
  • [47] BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
    Scheffler, Matthias
    Nogova, Lucia
    Gardizi, Masyar
    Christiaan, Marc
    Bos, Allardt
    Papachristou, Irini
    Sos, Martin
    Zander, Thomas
    Mattonet, Christian
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.
    Chu, Quincy
    Sangha, Randeep
    Hotte, Sebastien J.
    Deng, Qiqi
    Gyorffy, Steve
    Chand, Vikram K.
    Hirte, Hal W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    du Bois, A.
    Huober, J.
    Stopfer, P.
    Pfisterer, J.
    Wimberger, P.
    Loibl, S.
    Reichardt, V. L.
    Harter, P.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 370 - 375
  • [50] BARIS: A PHASE I TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF COMBINED BIBF 1120 AND RAD001 IN SOLID TUMORS AND TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF THE COMBINATION.
    Scheffler, Matthias
    Gardizi, Masyar
    Bos, Marc
    Nogova, Lucia
    Persigehl, Thorsten
    Wolf, Juergen
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S614 - S615
12345